tetano
Editor, Senior Moderator
Int Immunopharmacol
. 2020 Nov 3;107157.
doi: 10.1016/j.intimp.2020.107157. Online ahead of print.
Clinical characteristics and antibiotics treatment in suspected bacterial infection patients with COVID-19
Chengyin Liu[SUP] 1 [/SUP], Ying Wen[SUP] 1 [/SUP], Weiguo Wan[SUP] 1 [/SUP], Jingchao Lei[SUP] 1 [/SUP], Xuejun Jiang[SUP] 2 [/SUP]
Affiliations
Abstract
Coronavirus disease 2019 (COVID-19) pandemic has brought challenges to health and social care systems. However, the empirical use of antibiotics is still confusing. Presently, a total of 1123 patients with COVID-19 admitted to Renmin Hospital of Wuhan University was included in this retrospective cohort study. The clinical features, complications and outcomes were compared between the suspected bacterial infection and the no evidence of bacterial infection. The risk factors of mortality and the incidence of acute organ injury were analyzed. As a result, 473 patients were selected to suspected bacterial infection (SI) group based on higher white blood cell count and procalcitonin or bacterial pneumonia on chest radiography. 650 patients were selected to the no evidence of bacterial infection (NI) group. The SI group had more severely ill patients (70.2% vs. 39.8%), more death (20.5% vs. 2.2%), and more acute organ injury (40.2% vs. 11.2%). Antibiotics were found associated with improved mortality and an increased risk for acute organ injury in hospitalized patients with COVID-19. Intravenous moxifloxacin and meropenem increased the death rate in patients with suspected bacterial infection, while oral antibiotics reduced mortality in this group. Moreover, penicillin and meropenem treatments were associated with increased mortality of the patients with no evidence of bacterial infection. In conclusion, patients with suspected bacterial infection were more likely to have negative clinical outcomes than those without bacterial infection. Empirical use of antibiotics may not have the expected benefits.
Keywords: Antibiotics; Bacterial infection; COVID-19; Mortality.
. 2020 Nov 3;107157.
doi: 10.1016/j.intimp.2020.107157. Online ahead of print.
Clinical characteristics and antibiotics treatment in suspected bacterial infection patients with COVID-19
Chengyin Liu[SUP] 1 [/SUP], Ying Wen[SUP] 1 [/SUP], Weiguo Wan[SUP] 1 [/SUP], Jingchao Lei[SUP] 1 [/SUP], Xuejun Jiang[SUP] 2 [/SUP]
Affiliations
- PMID: 33187911
- PMCID: PMC7608018
- DOI: 10.1016/j.intimp.2020.107157
Abstract
Coronavirus disease 2019 (COVID-19) pandemic has brought challenges to health and social care systems. However, the empirical use of antibiotics is still confusing. Presently, a total of 1123 patients with COVID-19 admitted to Renmin Hospital of Wuhan University was included in this retrospective cohort study. The clinical features, complications and outcomes were compared between the suspected bacterial infection and the no evidence of bacterial infection. The risk factors of mortality and the incidence of acute organ injury were analyzed. As a result, 473 patients were selected to suspected bacterial infection (SI) group based on higher white blood cell count and procalcitonin or bacterial pneumonia on chest radiography. 650 patients were selected to the no evidence of bacterial infection (NI) group. The SI group had more severely ill patients (70.2% vs. 39.8%), more death (20.5% vs. 2.2%), and more acute organ injury (40.2% vs. 11.2%). Antibiotics were found associated with improved mortality and an increased risk for acute organ injury in hospitalized patients with COVID-19. Intravenous moxifloxacin and meropenem increased the death rate in patients with suspected bacterial infection, while oral antibiotics reduced mortality in this group. Moreover, penicillin and meropenem treatments were associated with increased mortality of the patients with no evidence of bacterial infection. In conclusion, patients with suspected bacterial infection were more likely to have negative clinical outcomes than those without bacterial infection. Empirical use of antibiotics may not have the expected benefits.
Keywords: Antibiotics; Bacterial infection; COVID-19; Mortality.